Insufficient scRNA-seq data for expression of PENK at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 70% | 6870.67 | 1840 / 2642 | 55% | 3.76 | 391 / 705 |
prostate | 62% | 589.81 | 151 / 245 | 54% | 2.62 | 271 / 502 |
adrenal gland | 40% | 4025.65 | 104 / 258 | 66% | 2155.99 | 151 / 230 |
ovary | 83% | 1220.14 | 150 / 180 | 9% | 2.04 | 38 / 430 |
intestine | 59% | 607.24 | 567 / 966 | 10% | 0.46 | 52 / 527 |
lung | 32% | 97.71 | 185 / 578 | 35% | 10.35 | 399 / 1155 |
esophagus | 46% | 274.86 | 667 / 1445 | 11% | 0.30 | 21 / 183 |
stomach | 33% | 397.37 | 118 / 359 | 15% | 0.57 | 44 / 286 |
eye | 0% | 0 | 0 / 0 | 43% | 1.79 | 34 / 80 |
breast | 24% | 177.54 | 108 / 459 | 13% | 1.27 | 143 / 1118 |
blood vessel | 31% | 237.49 | 408 / 1335 | 0% | 0 | 0 / 0 |
skin | 24% | 437.62 | 428 / 1809 | 6% | 0.28 | 29 / 472 |
pancreas | 0% | 0 | 0 / 328 | 29% | 3.11 | 52 / 178 |
heart | 25% | 151.99 | 218 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 24% | 1.30 | 11 / 45 |
uterus | 9% | 119.60 | 16 / 170 | 14% | 4.38 | 64 / 459 |
adipose | 18% | 84.56 | 222 / 1204 | 0% | 0 | 0 / 0 |
bladder | 5% | 9.95 | 1 / 21 | 7% | 0.38 | 37 / 504 |
thymus | 1% | 2.01 | 5 / 653 | 8% | 3.91 | 50 / 605 |
muscle | 6% | 17.82 | 45 / 803 | 0% | 0 | 0 / 0 |
kidney | 1% | 2.24 | 1 / 89 | 1% | 0.03 | 6 / 901 |
liver | 1% | 2.05 | 2 / 226 | 0% | 0.02 | 1 / 406 |
peripheral blood | 0% | 0.28 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019233 | Biological process | sensory perception of pain |
GO_0032355 | Biological process | response to estradiol |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0051867 | Biological process | general adaptation syndrome, behavioral process |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0071305 | Biological process | cellular response to vitamin D |
GO_0007165 | Biological process | signal transduction |
GO_0035902 | Biological process | response to immobilization stress |
GO_0002118 | Biological process | aggressive behavior |
GO_2000987 | Biological process | positive regulation of behavioral fear response |
GO_0007600 | Biological process | sensory perception |
GO_0045471 | Biological process | response to ethanol |
GO_0071871 | Biological process | response to epinephrine |
GO_0098586 | Biological process | cellular response to virus |
GO_0099538 | Biological process | synaptic signaling via neuropeptide |
GO_0071320 | Biological process | cellular response to cAMP |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_0001666 | Biological process | response to hypoxia |
GO_0035094 | Biological process | response to nicotine |
GO_0001662 | Biological process | behavioral fear response |
GO_0001964 | Biological process | startle response |
GO_0019226 | Biological process | transmission of nerve impulse |
GO_0009636 | Biological process | response to toxic substance |
GO_0035641 | Biological process | locomotory exploration behavior |
GO_0038003 | Biological process | G protein-coupled opioid receptor signaling pathway |
GO_0051592 | Biological process | response to calcium ion |
GO_0014009 | Biological process | glial cell proliferation |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0034466 | Cellular component | chromaffin granule lumen |
GO_0099013 | Cellular component | neuronal dense core vesicle lumen |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0043204 | Cellular component | perikaryon |
GO_0070852 | Cellular component | cell body fiber |
GO_0034592 | Cellular component | synaptic vesicle lumen |
GO_0043679 | Cellular component | axon terminus |
GO_0043025 | Cellular component | neuronal cell body |
GO_0030425 | Cellular component | dendrite |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0032280 | Cellular component | symmetric synapse |
GO_0001515 | Molecular function | opioid peptide activity |
GO_0031628 | Molecular function | opioid receptor binding |
GO_0005184 | Molecular function | neuropeptide hormone activity |
Gene name | PENK |
Protein name | Proenkephalin-A [Cleaved into: Synenkephalin; Met-enkephalin (Opioid growth factor) (OGF); PENK(114-133); PENK(143-183); Met-enkephalin-Arg-Gly-Leu; Leu-enkephalin; PENK(237-258); Met-enkephalin-Arg-Phe] Proenkephalin-A |
Synonyms | |
Description | FUNCTION: [Met-enkephalin]: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: [Leu-enkephalin]: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. .; FUNCTION: [Met-enkephalin-Arg-Phe]: Met-enkephalin-Arg-Phe neuropeptide acts as a strong ligand of Mu-type opioid receptor OPRM1. Met-enkephalin-Arg-Phe-binding to OPRM1 in the nucleus accumbens of the brain increases activation of OPRM1, leading to long-term synaptic depression of glutamate release. .; FUNCTION: [PENK(114-133)]: Increases glutamate release in the striatum and decreases GABA concentration in the striatum. .; FUNCTION: [PENK(237-258)]: Increases glutamate release in the striatum. . FUNCTION: Increases glutamate release in the striatum and decreases GABA concentration in the striatum. .; FUNCTION: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. . FUNCTION: Increases glutamate release in the striatum and decreases GABA concentration in the striatum. .; FUNCTION: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. . FUNCTION: Increases glutamate release in the striatum and decreases GABA concentration in the striatum. .; FUNCTION: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. . FUNCTION: Increases glutamate release in the striatum and decreases GABA concentration in the striatum. .; FUNCTION: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. . FUNCTION: Increases glutamate release in the striatum and decreases GABA concentration in the striatum. .; FUNCTION: Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. . |
Accessions | E5RIP6 ENST00000314922.3 ENST00000518770.1 E5RFR1 Q3B7B1 P01210 ENST00000517415.1 E5RJ72 H0YBT5 ENST00000523051.5 ENST00000518974.5 ENST00000451791.7 |